Finn
TRVI Biotechnology · Clinical stage · Single asset · Chronic cough · Thesis updated November 15, 2026

Funded into 2030, running alone in chronic cough

01 Running thesis

A cleared field and a clear path

Trevi is now fully in execution mode. The company recently started both of its pivotal Phase 3 trials for Haduvio in IPF-related chronic cough. It also aligned with the FDA on the path forward for non-IPF ILD, setting up another trial to start in early 2027.

The biggest recent change is the competitive landscape. Two rival chronic cough drugs failed over the summer. This leaves Trevi as the only company pursuing these specific cough markets. The bull case is stronger now because a crowded race has turned into a potential monopoly if Haduvio wins approval.

The financial picture remains strong. With about $299 million in cash as of late 2026, management expects to fund operations into 2030. This covers the critical clinical readouts without needing to sell more stock.

However, the bear case is tied strictly to clinical and commercial execution. Haduvio must prove it works where others failed. Also, management plans to keep global rights rather than partnering. This means Trevi will have to build its own sales team from scratch if the drug is approved.

Nov 2026▲Two competitor chronic cough programs failed, leaving Trevi alone in its targeted indications. The company also initiated its pivotal Phase 3 IPF trials.
Aug 2026→The Q2 2026 10-Q filing confirmed the company's financial and clinical trajectory remains unchanged, with operations proceeding as previously guided.
May 2026▲Trevi disclosed an April 2026 stock offering with about $162 million in net proceeds. Management now says cash runway extends into 2030, which lowers funding risk for the IPF Phase 3 program.
Mar 2026▲Trevi said it had a positive End-of-Phase 2 meeting with the FDA for Haduvio in IPF-related chronic cough. The update shifted the story toward Phase 3 execution.
Nov 2025▲Supportive Phase 1 safety and drug interaction updates reduced some open clinical questions. Cash runway into 2028 was also reaffirmed at that time.
Aug 2025▲Trevi reported positive full Phase 2b CORAL data and raised about $115 million in capital. The update strengthened the clinical case and reduced near-term financing pressure.
02 Business model

No sales yet, one future product

Trevi does not make money from product sales today. It is spending investor capital to test Haduvio in several types of chronic cough. The business only works if Haduvio wins approval, doctors prescribe it, and payers agree to cover it.

Haduvio is oral nalbuphine ER, meaning an extended-release pill form of nalbuphine. Trevi believes its central and peripheral action could help calm abnormal cough signaling. That is the main scientific reason for the company to exist.

The model is high risk but easy to understand. Clinical data create value, failed trials destroy value, and future profits would require Trevi to build a commercial sales effort alone. Keeping global rights means the company keeps all potential profits but takes on all the launch costs.

03 Product portfolio

One drug, several shots

Growth engine

Haduvio first IPF Phase 3 trial

The OCEAN-1 trial is a 52-week study with the main efficacy check at 24 weeks. This trial is the first major test of whether Phase 2 cough results can hold up in a larger study.

Growth engine

Haduvio second IPF Phase 3 trial

The OCEAN-2 trial is a 12-week confirmatory study. Success in both trials would be central to a possible FDA approval package.

Option

Haduvio for refractory chronic cough

Trevi is running a Phase 2b dose-ranging study called LAKE. An interim update to check the required sample size is due in early 2027.

Option

Haduvio for non-IPF ILD chronic cough

After aligning with the FDA, Trevi plans to start a Phase 2 study in early 2027 to widen Haduvio beyond IPF lung scarring diseases.

04 Business segments

A single development company

Haduvio development100%growing fast
Commercial product revenue0%flat

Trevi reports as a clinical-stage company with no commercial products. For this page, the mix reflects the late 2026 financial context: essentially all economic exposure is Haduvio development, while commercial product revenue is zero.

05 Risk factors

What could break

Phase 3 IPF failure

High impact · Medium odds

The main value driver is Haduvio in IPF-related chronic cough. If the primary cough endpoints miss in the new OCEAN trials, Trevi would have few other ways to support its valuation.

We watchTop-line data from the two IPF Phase 3 trials, especially the 24-week endpoint in the first trial.

Single-product dependence

High impact · High odds

Trevi has one drug candidate. The company is testing it in several cough settings, but those programs still depend on the same molecule. A safety or regulatory problem with Haduvio would hit the whole company.

We watchSafety updates, dropout rates, dose changes, and any FDA requests tied to Haduvio.

Launch buildout risk

Medium impact · Medium odds

Trevi plans to retain global rights rather than partnering with a larger pharmaceutical company. Building a specialized sales and marketing infrastructure from scratch will present major operational and financial challenges.

We watchEarly hiring plans, cash burn updates, and launch spending guidance as Phase 3 data gets closer.

Refractory chronic cough trial sizing

Medium impact · Medium odds

The ongoing LAKE Phase 2b trial will have an interim sample size check. If the trial is expanded significantly, it could suggest a smaller drug effect or higher variability than hoped.

We watchThe sample size reestimation update for the LAKE trial expected in early Q1 2027.
06 Quick answers

In one breath

Does Trevi Therapeutics have any approved drugs?

No. Trevi is a clinical-stage biotech, so it does not have approved products or commercial product revenue today. Its only drug candidate is Haduvio.

What is Haduvio being tested for?

Haduvio is being tested for chronic cough in IPF, refractory chronic cough, and chronic cough in non-IPF ILD. The lead program is currently in Phase 3 trials.

What is the biggest near-term thing to watch?

Investors should watch the interim sample size update for the LAKE trial in early 2027, followed by top-line results from the Phase 3 IPF trials later on.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Trevi Therapeutics Q2 2026 Form 10-Q
  2. Trevi Therapeutics Q3 2026 Earnings Transcript
  3. Trevi Therapeutics Q1 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Trevi Therapeutics, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today